ZOH é: A prospective study of the use of biosimilar filgrastim Zarzio® in clinical practice in patients treated with chemotherapy for lymphoid malignancies

The ZOH é study showed that Zarzio® is readily used for prophylaxis of chemotherapy-induced neutropenia in France, and clinicians’ assessment of febrile neutropenia risk is driven by patient factors more than the EORTC risk category of the chemotherapy regimen. Maintenance of dose intensity was high, es pecially in non-Hodgkin lymphoma patients at high risk of neutropenia. Zarzio® safety profile was confirmed.

Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Gandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, Inna Voronina, Khaled Benabed, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Corinne Haioun, Philippe Solal-C éligny Source Type: research